HUE054851T2 - Köztitermékek epesav-származékok, különösen obetikolsav szintéziséhez - Google Patents
Köztitermékek epesav-származékok, különösen obetikolsav szintéziséhezInfo
- Publication number
- HUE054851T2 HUE054851T2 HUE17725740A HUE17725740A HUE054851T2 HU E054851 T2 HUE054851 T2 HU E054851T2 HU E17725740 A HUE17725740 A HU E17725740A HU E17725740 A HUE17725740 A HU E17725740A HU E054851 T2 HUE054851 T2 HU E054851T2
- Authority
- HU
- Hungary
- Prior art keywords
- intermediates
- synthesis
- obeticholic
- acid derivatives
- acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J21/005—Ketals
- C07J21/006—Ketals at position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J21/005—Ketals
- C07J21/008—Ketals at position 17
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J33/00—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J33/00—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J33/002—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
- C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0088—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing unsubstituted amino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
- C07J71/001—Oxiranes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
- C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Toxicology (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1608777.7A GB201608777D0 (en) | 2016-05-18 | 2016-05-18 | Compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE054851T2 true HUE054851T2 (hu) | 2021-10-28 |
Family
ID=56320629
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE17725740A HUE054851T2 (hu) | 2016-05-18 | 2017-05-18 | Köztitermékek epesav-származékok, különösen obetikolsav szintéziséhez |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US10968250B2 (hu) |
| EP (2) | EP3458469B1 (hu) |
| JP (1) | JP7034093B2 (hu) |
| KR (1) | KR102458265B1 (hu) |
| CN (1) | CN109415407B (hu) |
| AU (1) | AU2017266539B2 (hu) |
| CA (1) | CA3024281A1 (hu) |
| EA (1) | EA037584B1 (hu) |
| ES (2) | ES2878577T3 (hu) |
| GB (1) | GB201608777D0 (hu) |
| HR (1) | HRP20211128T1 (hu) |
| HU (1) | HUE054851T2 (hu) |
| MX (1) | MX378591B (hu) |
| PT (1) | PT3458469T (hu) |
| WO (1) | WO2017199033A1 (hu) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201608776D0 (en) * | 2016-05-18 | 2016-06-29 | Dextra Lab Ltd | Methods and compounds |
| EP3431486A1 (en) * | 2017-07-18 | 2019-01-23 | Bionice, S.L.U. | Process and intermediates for the synthesis of obeticholic acid and derivatives thereof |
| GB201812382D0 (en) | 2018-07-30 | 2018-09-12 | Nzp Uk Ltd | Compounds |
| CN111138509B (zh) * | 2018-11-02 | 2022-12-06 | 东莞东阳光药物研发有限公司 | 奥贝胆酸的制备方法 |
| CN111072744B (zh) * | 2019-12-03 | 2021-09-14 | 江苏佳尔科药业集团股份有限公司 | 一种以ba为原料合成熊去氧胆酸的方法 |
| CN114315945A (zh) * | 2020-09-28 | 2022-04-12 | 四川澄华生物科技有限公司 | 一种胆甾酸及其衍生物的除杂方法 |
| CN112341516B (zh) * | 2020-11-14 | 2022-07-15 | 湖南科瑞生物制药股份有限公司 | 5,6-环氧类固醇类化合物及其制备方法和应用 |
| WO2023081657A2 (en) * | 2021-11-02 | 2023-05-11 | Sandhill One, Llc | High purity non-animal derived udca |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2624748A (en) | 1950-09-09 | 1953-01-06 | Upjohn Co | Bisnorchola-4, 6-dien-3-one-22-al |
| US4289872A (en) | 1979-04-06 | 1981-09-15 | Allied Corporation | Macromolecular highly branched homogeneous compound based on lysine units |
| US5229490A (en) | 1987-05-06 | 1993-07-20 | The Rockefeller University | Multiple antigen peptide system |
| EP0636156B1 (en) | 1992-04-14 | 1997-07-30 | Cornell Research Foundation, Inc. | Dendritic based macromolecules and method of production |
| WO1994019366A1 (en) | 1993-02-26 | 1994-09-01 | Magainin Pharmaceuticals Inc. | Chemical synthesis of squalamine |
| US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| IL157816A0 (en) | 2001-03-12 | 2004-03-28 | Roberto Pellicciari | Steroids as agonists for fxr |
| US20090062256A1 (en) | 2001-06-01 | 2009-03-05 | Bristol-Myers Squibb Pharma Company | LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Abeta PROTEIN PRODUCTION |
| CA2466027C (en) | 2001-11-07 | 2013-01-08 | Nektar Therapeutics Al, Corporation | Branched polymers and their conjugates |
| EP1568706A1 (en) | 2004-02-26 | 2005-08-31 | Intercept Pharmaceuticals, Inc. | Novel steroid agonist for FXR |
| ITMI20050912A1 (it) | 2005-05-19 | 2006-11-20 | Erregierre Spa | Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici |
| CN101374854A (zh) * | 2006-01-12 | 2009-02-25 | 三菱化学株式会社 | 甾类化合物的制备方法 |
| JP2007210888A (ja) * | 2006-01-12 | 2007-08-23 | Mitsubishi Chemicals Corp | ステロイド化合物の製造方法 |
| CN101395170A (zh) | 2006-02-14 | 2009-03-25 | 英特塞普特药品公司 | 用于预防或治疗fxr介导的疾病或状态的作为fxr配体的胆汁酸衍生物 |
| US7932244B2 (en) | 2006-06-27 | 2011-04-26 | Intercept Pharmaceuticals, Inc. | Bile acid derivatives as FXR ligands for the prevention or treatment of FXR-mediated diseases or conditions |
| EA017714B1 (ru) | 2007-01-19 | 2013-02-28 | Интерсепт Фармасьютикалз, Инк. | Модуляторы tgr5 и способы их применения |
| EA020310B1 (ru) | 2008-07-30 | 2014-10-30 | Интерсепт Фармасьютикалз, Инк. | Модуляторы рецептора tgr5 и их применение |
| AU2009316566B9 (en) | 2008-11-19 | 2014-05-15 | Intercept Pharmaceuticals, Inc. | TGR5 modulators and method of use thereof |
| EP3150620B1 (en) | 2008-11-19 | 2020-01-08 | Intercept Pharmaceuticals, Inc. | Tgr5 modulators and methods of use thereof |
| CA2769203A1 (en) | 2009-07-29 | 2011-02-03 | University Of Chicago | Liver x receptor agonists |
| KR20190121871A (ko) | 2012-06-19 | 2019-10-28 | 인터셉트 파마슈티컬즈, 인크. | 오베티콜산의 제조법, 용도 및 고체 형태 |
| EP2912013B1 (en) | 2012-10-26 | 2017-10-11 | Intercept Pharmaceuticals, Inc. | Process for preparing bile acid derivatives |
| CA2891348C (en) | 2012-11-28 | 2020-04-28 | Intercept Pharmaceuticals, Inc. | Treatment of pulmonary disease |
| US20140206657A1 (en) * | 2013-01-18 | 2014-07-24 | City Of Hope | Bile acid analog tgr5 agonists |
| CN108245523B (zh) | 2013-05-14 | 2021-03-26 | 英特塞普特医药品公司 | 作为法尼醇x受体调节剂的胆汁酸的11-羟基衍生物及其氨基酸共轭物 |
| SG11201509370UA (en) | 2013-05-24 | 2015-12-30 | Nestec Sa | Pathway specific assays for predicting irritable bowel syndrome diagnosis |
| US10166246B2 (en) | 2014-05-27 | 2019-01-01 | City Of Hope | TGR5 agonist complexes for treating diabetes and cancer |
| LT3626725T (lt) | 2014-05-29 | 2023-03-10 | Bar Pharmaceuticals S.R.L. | Cholano dariniai skirti naudoti ligų, kurių atsiradimui tarpininkauja fxr ir tgr5/gpbar1, gydymui ir (arba) profilaktikai |
| KR20170094184A (ko) | 2014-11-06 | 2017-08-17 | 이난타 파마슈티칼스, 인코포레이티드 | Fxr/tgr5 작용제로서의 담즙산 유사체 및 이의 이용 방법 |
| JP6724004B2 (ja) | 2014-11-19 | 2020-07-15 | エヌゼットピー ユーケー リミテッド | ステロイドＦＸＲモジュレーター製造のための中間体としての５β−６−アルキル−７−ヒドロキシ−３−オンステロイド |
| MX381239B (es) | 2014-11-19 | 2025-03-12 | Nzp Uk Ltd | Esteroides de 6.alfa.-alquil-6,7-diona como intermedios para la producción de moduladores esteroideos del receptor x farnesoide (fxr). |
| BR112017010319B1 (pt) * | 2014-11-19 | 2023-04-11 | NZP UK Limited | Esteroides 6-alquil-7-hidróxi-4-en-3-ona e processo para a preparação dos mesmos |
| CA2968305A1 (en) * | 2014-11-19 | 2016-05-26 | NZP UK Limited | 6.alpha.-alkyl-3,7-dione steroids as intermediates for the production of steroidal fxr modulators |
| US11578097B2 (en) | 2014-11-26 | 2023-02-14 | Enanta Pharmaceuticals, Inc. | Tetrazole derivatives of bile acids as FXR/TGR5 agonists and methods of use thereof |
| WO2016086134A1 (en) | 2014-11-26 | 2016-06-02 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof |
| US10208081B2 (en) | 2014-11-26 | 2019-02-19 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof |
| MX2017006833A (es) | 2014-11-26 | 2018-02-13 | Enanta Pharm Inc | Análogos de ácido biliar como agonistas de fxr/tgr5 y métodos para el uso de los mismos. |
| CN105348365A (zh) * | 2014-12-03 | 2016-02-24 | 四川百利药业有限责任公司 | 一种胆酸衍生物及其制备方法、药物组合物和用途 |
| CN106279328A (zh) | 2015-05-20 | 2017-01-04 | 重庆药友制药有限责任公司 | 一种制备6α-烷基鹅去氧胆酸的方法 |
| SI3310801T1 (sl) | 2015-06-19 | 2021-10-29 | Intercept Pharmaceuticals Inc | Modulatorji TGR5 in postopki za uporabo le-teh |
| CN106397522A (zh) | 2015-07-31 | 2017-02-15 | 中国人民解放军军事医学科学院毒物药物研究所 | 3,7‑二（叔丁基二甲基硅基氧基）‑6‑烯‑5β‑胆烷‑24‑酸甲酯 |
| CN106478759A (zh) | 2015-08-31 | 2017-03-08 | 陕西合成药业股份有限公司 | 奥贝胆酸衍生物及其制备方法和用途 |
| CN106478756A (zh) | 2015-09-02 | 2017-03-08 | 中美华世通生物医药科技（武汉）有限公司 | Oca-e单晶及其制备方法和用途 |
| CN106518946A (zh) | 2015-09-10 | 2017-03-22 | 上海迪诺医药科技有限公司 | 磺酰脲衍生物、其药物组合物及应用 |
| GB201608779D0 (en) | 2016-05-18 | 2016-06-29 | Dextra Lab Ltd | Methods and compounds |
| GB201608776D0 (en) | 2016-05-18 | 2016-06-29 | Dextra Lab Ltd | Methods and compounds |
-
2016
- 2016-05-18 GB GBGB1608777.7A patent/GB201608777D0/en not_active Ceased
-
2017
- 2017-05-18 ES ES17725740T patent/ES2878577T3/es active Active
- 2017-05-18 CN CN201780030532.1A patent/CN109415407B/zh active Active
- 2017-05-18 WO PCT/GB2017/051385 patent/WO2017199033A1/en unknown
- 2017-05-18 EP EP17725740.9A patent/EP3458469B1/en active Active
- 2017-05-18 EA EA201892514A patent/EA037584B1/ru unknown
- 2017-05-18 PT PT177257409T patent/PT3458469T/pt unknown
- 2017-05-18 AU AU2017266539A patent/AU2017266539B2/en active Active
- 2017-05-18 EP EP21160246.1A patent/EP3848382B1/en active Active
- 2017-05-18 MX MX2018014164A patent/MX378591B/es unknown
- 2017-05-18 CA CA3024281A patent/CA3024281A1/en active Pending
- 2017-05-18 HU HUE17725740A patent/HUE054851T2/hu unknown
- 2017-05-18 JP JP2018560597A patent/JP7034093B2/ja active Active
- 2017-05-18 HR HRP20211128TT patent/HRP20211128T1/hr unknown
- 2017-05-18 ES ES21160246T patent/ES2970336T3/es active Active
- 2017-05-18 US US16/302,059 patent/US10968250B2/en active Active
- 2017-05-18 KR KR1020187035834A patent/KR102458265B1/ko active Active
-
2021
- 2021-02-26 US US17/186,272 patent/US11479577B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3848382A1 (en) | 2021-07-14 |
| BR112018073488A2 (pt) | 2019-04-09 |
| EA037584B1 (ru) | 2021-04-16 |
| US20210179661A1 (en) | 2021-06-17 |
| HRP20211128T1 (hr) | 2022-01-07 |
| KR102458265B1 (ko) | 2022-10-25 |
| MX2018014164A (es) | 2019-04-01 |
| US20190284227A1 (en) | 2019-09-19 |
| JP7034093B2 (ja) | 2022-03-11 |
| KR20190009322A (ko) | 2019-01-28 |
| EA201892514A1 (ru) | 2019-05-31 |
| CN109415407A (zh) | 2019-03-01 |
| EP3458469A1 (en) | 2019-03-27 |
| EP3848382B1 (en) | 2023-11-29 |
| MX378591B (es) | 2025-03-11 |
| CA3024281A1 (en) | 2017-11-23 |
| AU2017266539B2 (en) | 2021-04-15 |
| CN109415407B (zh) | 2021-08-17 |
| PT3458469T (pt) | 2021-06-11 |
| JP2019516720A (ja) | 2019-06-20 |
| EP3458469B1 (en) | 2021-04-14 |
| GB201608777D0 (en) | 2016-06-29 |
| ES2878577T3 (es) | 2021-11-19 |
| AU2017266539A1 (en) | 2018-11-15 |
| US11479577B2 (en) | 2022-10-25 |
| ES2970336T3 (es) | 2024-05-28 |
| EP3848382C0 (en) | 2023-11-29 |
| US10968250B2 (en) | 2021-04-06 |
| WO2017199033A1 (en) | 2017-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1254057A1 (zh) | 用於製備膽汁酸衍生物的方法和中間體 | |
| IL304455A (en) | Methods and intermediates for the preparation of bile acid derivatives | |
| PT3458469T (pt) | Intermediários para a síntese de derivados de ácido biliar, em particular de ácido obeticólico | |
| EP3158073B8 (en) | Compositions and methods for making (s)-norcoclaurine and (s)-norlaudanosoline, and synthesis intermediates thereof | |
| HK1232220A1 (zh) | 用於治療心血管疾病的 -苄基異喹啉衍生物 | |
| PL3313853T3 (pl) | Sposób syntezy pochodnych rapamycyny | |
| IL272119A (en) | Bile acid derivatives are isotopically labeled | |
| DK3200779T3 (en) | Novel anthranilic acid derivatives | |
| ZA201803250B (en) | New 5-azido-5-deoxy-2 :3-isopropylidene-d-arabinose compounds; their method of manufacture and their use for the synthesis of ara-n3, kdo-n3 and 4ekdo-n3 | |
| IL259073A (en) | History of abscisic acid - converted at the 3' position | |
| IL265634A (en) | Novel 5-substituted imidazolylmethyl derivatives | |
| HRP20181918T1 (hr) | Postupak za sintezu derivata benzazepina | |
| IS2977B (is) | Aðferð til framleiðslu á milliefnum sem eru nytsamleg við nýsmíði á elúxadólíni | |
| EP3177280A4 (en) | Synthesis of 2,2,2-trifluoroethanethiol | |
| GB201719127D0 (en) | Methylchloroperoxybenzoic acid drug intermediates synthesis method | |
| EP3288560A4 (en) | Methods for the synthesis of ceragenins | |
| GB201715085D0 (en) | 2-furanacrylic acid drug intermediates synthesis method | |
| GB201715112D0 (en) | P-methoxphenylacetic acid drug intermediates synthesis method | |
| GB201714451D0 (en) | 3-methoxy-4-hydroxy-5-nitrobenzoic acid drug intermediates synthesis method | |
| GB201700012D0 (en) | Iodoacetylcholine synthesis method as pharmaceutical intermediates | |
| GB201709978D0 (en) | Drug intermediates p-benzoylbenzoic acid synthesis method | |
| SI3320102T1 (sl) | Metoda za sintezo pentostatina | |
| HUP1500451A2 (en) | Processes for the preparation of 1,4,7-triaza-cyclononane derivatives and intermediates | |
| GB201523002D0 (en) | Thiazolidine acid drug intermediates LN- acetyl-thia-proline synthesis method |